Over the last decade, I have been advocating for revamping drug regulatory laws in India. I have encountered much opposition in the process – some from the pharmaceutical industry and a lot more from public health activists working on access to medicine, many of whom look at quality and price as binaries in the context of our drug supply.
I hold no grudges against those with opposing viewpoints. Quite honestly, it makes the job more interesting. However, I do have a problem with the complete lack of disclosure by some public health activists engaging with the media on some of these issues.
